27 citations
,
October 2020 in “Drugs” This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.
9 citations
,
April 2021 in “Expert opinion on pharmacotherapy” This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.
4 citations
,
July 2022 in “Clinical Cosmetic and Investigational Dermatology” This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.
3 citations
,
March 2019 in “Journal of Pigmentary Disorders” This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.
June 2026 in “International Journal of Innovative Technologies in Social Science” This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.